| 代码 | 简称 | 今日涨跌幅（%） | 今日换手率（%） | 主力资金流量（万元） | | --- | --- | --- | --- | --- | | 600673 | 东阳光 | -3.21 | 2.68 | -14491.47 | | 000833 | 粤桂股份 | -2.80 | 6.94 | -7373.89 | | 600682 | 南京新百 | -4.53 | 3.60 | -5351.45 | | 600881 | 亚泰集团 | -3.77 | 4.31 | -4799.74 | | 000652 | 泰达股份 | -4.07 | 3.04 | -4717.73 | | 000753 | 漳州发展 | -3.90 | 8.00 | -3754.31 | | 000025 | 特力A | -2.82 | 3.06 | -2421.36 | | 600805 | 悦达投资 | -2.56 | 3.75 | -2279.05 | | 000421 | 南京公用 | -3.25 | 2.68 | -1205.13 | | 000523 | 红棉股份 | -2.67 | 1.90 | -617. ...

| 证券代码：600673 | 证券简称：东阳光 | | 编号：临 号 | 2025-51 | | --- | --- | --- | --- | --- | | 债券代码：242444 | 债券简称：25 东科 | 01 | | | 广东东阳光科技控股股份有限公司 关于控股股东部分股份解质押及质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 控股股东深圳市东阳光实业发展有限公司（以下简称"深圳东阳光实业"） 持有本公司股份 617,650,241 股，占公司总股本的 20.52%；截至本次股份解质押 及质押完成后，深圳东阳光实业持有本公司股份累计质押数量为 531,527,254 股， 占其持股数量的 86.06%。 截至本公告披露日，公司控股股东累计质押股份数量为 531,527,254 股， 占其持股数量的 86.06%；控股股东及其一致行动人累计质押股份数量为 1,244,117,797 股，占其合计持股数量的 78.34%。 一、本次股份解质押及质押基本情况 广东东阳光科技控股股份有限公司（ ...

投资基金 合计 1,588,080,370 52.77 1,264,388,597 1,244,117,797 78.34 41.34 0 0 0 0 三、上市公司控股股东股份质押情况 | 证券代码：600673 证券简称：东阳光 | | | | | | | 编号：临 | | 2025-51 | 号 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 债券代码：242444 债券简称：25 东科 01 | | | | | | | | | | | | | | | | 广东东阳光科技控股股份有限公司 | | | | | | | | | | | | | | | | 关于控股股东部分股份解质押及质押的公告 | | | | | | | | | | | | | | | | 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 | | | | | | | | | | | | | | | | 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 | ...

证券之星消息，8月26日综合板块较上一交易日上涨1.13%，综艺股份领涨。当日上证指数报收于 3868.38，下跌0.39%。深证成指报收于12473.17，上涨0.26%。综合板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 600770 | 综艺股份 | 6.25 | 2.97% | 65.97万 | 4.10亿 | | 000632 | 三木集团 | 4.22 | 2.43% | 19.18万 | 8016.47万 | | 000753 | 漳州发展 | 7.44 | 2.20% | 127.07万 | 9.34亿 | | 600673 | 东阳光 | 20.57 | 1.68% | 113.75万 | 23.82亿 | | 600881 | 亚泰集团 | 2.12 | 1.44% | 137.56万 | 2.91亿 | | 002758 | 浙农股份 | 9.36 | 0.75% | 7.84万 | 7336.00万 | | 000421 | 南京公用 | 6.76 ...

中证报中证网讯(记者武卫红)日前，第九届特发性肺纤维化(IPF)峰会在美国波士顿召开。作为全球肺纤 维化领域的权威学术会议，本届峰会聚焦IPF治疗最新突破与研发进展。东阳光（600673）药 (06887.HK)受邀出席并在主议程中首次披露其自主研发的抗纤维化1类新药伊非尼酮(HEC585)的II期临 床试验关键数据，其明确的疗效优势与安全性引发关注。 据介绍，伊非尼酮是国产首个进入III期临床的特发性肺纤维化原研新药，具备多靶点、多通路的独特作 用机制。通过协同抑制TNF-α与TGF-β1释放、阻断TGF-β1-smad信号通路，形成了广泛的抗纤维化网 络。临床前数据表明其抑制成纤维细胞增殖的IC50优于吡非尼酮200-500倍。 此次公布的II期临床研究为一项多中心、随机、安慰剂(双盲)及阳性药物(开放)平行对照的II期临床研 究，旨在评价盐酸伊非尼酮片在特发性肺纤维化(IPF)患者中的有效性和安全性。试验共纳入224例IPF 患者。结果显示，伊非尼酮200mg组在治疗24周后，患者FVC(用力肺活量)较基线仅下降3.3mL，相比 安慰剂组改善超过80mL(P＜0.1)，延缓肺功能下降比例高达96%，远优 ...

Investment Rating - The report maintains a rating of "Increase" for the industry [4] Core Insights - The basic chemical sector is experiencing a configuration opportunity, with the index declining by 59.5% from a peak of 9565.18 points in September 2021 to a low of 3876.11 points in February 2024 [1] - The construction project growth rate in the chemical industry has turned negative at -7.3% by Q1 2025, indicating a slowdown [1] - The basic chemical index saw a cumulative increase of 12.6% from July 11 to August 22, 2024, while the petroleum and petrochemical index rose by 5.6% during the same period [1] - Institutional holdings in the basic chemical sector peaked in Q3 2021 at 6.69%, but have since declined to 3.72% by Q2 2025 [1] Summary by Sections AI for Science and Material Development - The report emphasizes the importance of AI for Science (AI4S) in revolutionizing material development, particularly through the use of molecular dynamics (MD) and density functional theory (DFT) [2] - The development of algorithm chip-based atomic-level computing APU chips by Dao Technology is highlighted, which significantly improves computational power and reduces energy consumption [2] - Dao Technology's subsidiary, Hexi, is building an AI4S intelligent computing center to support material research [2] Investment Opportunities in AI4S - AI4S is rapidly penetrating the pharmaceutical and chemical industries, with 41 license-out transactions in the Chinese innovative drug sector in Q1 2025, totaling $36.929 billion [3] - AI is expected to replace traditional drug development processes, significantly speeding up research and reducing costs [3] - The report identifies potential investment opportunities in AI4S-related materials, including perovskite, solid-state batteries, semiconductor materials, and more [3] Key Stocks - The report lists key stocks with a "Buy" rating, including Dongyangguang, Jingtai Holdings, Zhongyan Dadi, and Weixing Chemical, with projected earnings per share (EPS) and price-to-earnings (PE) ratios provided for 2024 to 2027 [7]

第九届特发性肺纤维化(IPF)峰会于2025年8月19日至21日在美国波士顿召开。东阳光（600673）药 (06887)亮相本次峰会，首席科学家林凯博士在大会主议程中首次公开披露在研抗纤维化创新药伊非尼 酮(HEC585)的II期临床试验关键数据，这一重要发布瞬间吸引了在场众多科学家的目光，引发了广泛关 注与热烈讨论，成为峰会的一大焦点。 众所众知，美国IPF峰会作为全球肺纤维化研究领域最具权威性和影响力的学术会议之一，汇聚全球顶 尖科学家，集中展示领域内最新前沿研究成果，聚焦全球肺纤维化治疗药物的研发进程、新兴生物学机 制的解析，旨在推动特发性肺纤维化治疗实现变革性突破。 而在此次峰会亮相的伊非尼酮是东阳光药自主研发的国产首个进入III期临床的IPF原研新药，同时可以 拓展进行性纤维化性间质性肺疾病(PF-ILD)、乙肝肝纤维化、间质性肺炎等疾病。通过同时抑制TNF-α 及TGF-β1的释放以及阻断TGF-β1-smad信号通路，从而抑制胶原等细胞外基质的沉积和纤维化进展，并 通过NR4A1、BMP2等靶点调节PI3K-AKT、MAPK和Hippo信号通路，形成广泛的抗纤维化网络以达到 治疗作用。 多靶点 ...

Core Insights - The 9th Idiopathic Pulmonary Fibrosis (IPF) Summit will be held in Boston from August 19 to 21, 2025, where Dongyangguang Pharmaceutical will present key data from the Phase II clinical trial of its innovative anti-fibrotic drug, HEC585 [1] - HEC585 is the first domestically developed IPF drug to enter Phase III clinical trials and has potential applications in various fibrotic diseases [1][5] - The summit is a significant event in the field of pulmonary fibrosis research, showcasing the latest advancements and aiming for transformative breakthroughs in treatment [1] Company Insights - HEC585 has demonstrated a multi-targeted mechanism that effectively inhibits fibrosis, showing potential as a "Best in Class" drug [2] - The Phase II clinical trial involved 270 participants and showed that HEC585 significantly delayed the decline in Forced Vital Capacity (FVC) compared to placebo, with a notable improvement of over 80 mL [2] - The safety profile of HEC585 is favorable, with adverse reactions comparable to placebo and lower incidence of skin-related issues compared to the existing treatment, pirfenidone [3] Industry Insights - IPF is a chronic, progressive disease with a median survival of only 2-3 years post-diagnosis, affecting an increasing number of patients globally [4] - The global incidence of IPF is projected to reach 1.8 million by 2025, with a compound annual growth rate of 3.0% from 2015 to 2022 [4] - Currently, only two drugs are approved for IPF treatment, and many new drug developments have failed, highlighting the challenges in this therapeutic area [4][6] - HEC585 is the only innovative drug in the domestic market that has completed head-to-head clinical trials against pirfenidone, demonstrating superior efficacy [6]

Core Viewpoint - Dongyang Sunshine Pharmaceutical (06887.HK) has experienced a significant decline in stock price since its debut on the Hong Kong Stock Exchange, reflecting poor financial performance and market sentiment [1] Financial Performance - Dongyang Sunshine Pharmaceutical's stock closed at HKD 49.00, down 4.39%, marking five consecutive days of decline, with an intraday low of HKD 48.36, the lowest since its listing [1] - The company reported a 37% year-on-year decline in revenue for 2024, with operating profit down 78.4% and net profit down 97.55% [1] - Revenue figures for 2022, 2023, and 2024 were CNY 3.814 billion, CNY 6.386 billion, and CNY 4.019 billion respectively, with gross profit of CNY 2.922 billion, CNY 5.077 billion, and CNY 3.059 billion [1] - Operating profits for the same years were CNY -793 million, CNY 1.766 billion, and CNY 381 million, while net profits were CNY -1.416 billion, CNY 1.014 billion, and CNY 24.8 million [1] Market Reaction - On its first trading day, Dongyang Sunshine Pharmaceutical's stock closed at HKD 59.90, up 4.17%, with an intraday high of HKD 62.30, reflecting an 8.35% increase [1]

近日，国际权威机构弗若斯特沙利文正式授予东阳光"全球生态繁育冬虫夏草开创者"证书，标志着东阳 光在冬虫夏草生态繁育领域的全球领先地位得到权威认证。 一方面，东阳光运用智能生态科技和大数据分析技术，高度还原野生冬虫夏草在高原生长所需的温度、 湿度、气压等必要条件，让冬虫夏草遵循自然生长规律进行生长。另一方面，据多家专业机构鉴定，东 阳光冬虫夏草在菌种、虫种、外观性状、化学成分、滋补作用等方面，与野生冬虫夏草高度一致。凭借 该重大突破，东阳光获批建立全国唯一一个以冬虫夏草命名的重点实验室——国家中医药管理局"冬虫 夏草繁育与产品研发重点研究室"。 目前，东阳光已建成近40万㎡的冬虫夏草生态繁育基地，不仅打破了"冬虫夏草只能野生"的行业认知， 更率先推开冬虫夏草生态繁育产业化的大门，实现规模化稳定生产。据悉，该基地年产量已达60吨以 上，可全年365天供应新鲜冬虫夏草，实现了行业供给侧的历史性突破。 光环背后，是东阳光集团旗下品牌东阳光鲜虫草扎根冬虫夏草领域18年的厚积薄发。从突破资源桎梏， 到树立品质标杆，再到擘画全球版图，东阳光鲜虫草已探索出一条从破局到掌舵的先驱路，推动冬虫夏 草产业构建起产量丰、品质优、品牌 ...